Terms: = Germ cell tumor AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1 AND Treatment
6 results:
1. Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.
Kuo SH; Yang SY; You SL; Lien HC; Lin CH; Lin PH; Huang CS
Oncotarget; 2017 Mar; 8(13):20925-20938. PubMed ID: 28178648
[TBL] [Abstract] [Full Text] [Related]
2. Validation of genetic sequence variants as prognostic factors in early-stage head and neck squamous cell cancer survival.
Azad AK; Bairati I; Samson E; Cheng D; Mirshams M; Qiu X; Savas S; Waldron J; Wang C; Goldstein D; Xu W; Meyer F; Liu G
Clin Cancer Res; 2012 Jan; 18(1):196-206. PubMed ID: 22076708
[TBL] [Abstract] [Full Text] [Related]
3. Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells.
Mann A; Tyndale RF
Eur J Neurosci; 2010 Apr; 31(7):1185-93. PubMed ID: 20345925
[TBL] [Abstract] [Full Text] [Related]
4. Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples.
Rae JM; Cordero KE; Scheys JO; Lippman ME; Flockhart DA; Johnson MD
Pharmacogenetics; 2003 Aug; 13(8):501-7. PubMed ID: 12893988
[TBL] [Abstract] [Full Text] [Related]
5. Astroglial CYP1B1 up-regulation in inflammatory/oxidative toxic conditions: IL-1beta effect and protection by N-acetylcysteine.
Malaplate-Armand C; Ferrari L; Masson C; Siest G; Batt AM
Toxicol Lett; 2003 Mar; 138(3):243-51. PubMed ID: 12565201
[TBL] [Abstract] [Full Text] [Related]
6. MGMT- and P450 3A-inhibitors do not sensitize glioblastoma cell cultures against nitrosoureas.
Kirches E; Scherlach C; von Bossanyi P; Schneider T; Szibor R; Kutz E; Warich-Kirches M; Dietzmann K
Clin Neuropathol; 1999; 18(1):1-8. PubMed ID: 9988132
[TBL] [Abstract] [Full Text] [Related]
